In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Arthritis & Rheumatism

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.30242PMID 21305508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alterations on peripheral blood B-cell subpopulations in very early arthritis patients.

  2010cited by this paper
• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

  2010cited by this paper
• Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle

  2010cited by this paper
• Current aspects of anti-CD20 therapy in rheumatoid arthritis.

  2010cited by this paper
• Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis

  2009cited by this paper
• Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

  2009cited by this paper
• Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor

  2009cited by this paper
• IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation.

  2009cited by this paper
• The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells

  2009cited by this paper
• Interleukin-6 as a key player in systemic inflammation and joint destruction.

  2009cited by this paper
• Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura.

  2009cited by this paper
• IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

  2008cited by this paper
• Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti‐CD20 therapy: the B‐cell roadblock hypothesis

  2008cited by this paper
• Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

  2008cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008influential reference
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses.

  2007cited by this paper
• Interleukin-6 and rheumatic diseases

  2006cited by this paper
• Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer

  2006cited by this paper
• Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61

  2005cited by this paper
• Humanized anti-interleukin-6 receptor antibody

  2005cited by this paper
• Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus

  2005cited by this paper
• Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

  2005cited by this paper
• Rationale for interleukin-6 blockade in systemic lupus erythematosus

  2004cited by this paper
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

  2004cited by this paper
• Plasma Cell Survival Is Mediated by Synergistic Effects of Cytokines and Adhesion-Dependent Signals1

  2003cited by this paper
• Roles of B cells in rheumatoid arthritis

  2003cited by this paper
• Human Immunoglobulin M Memory B Cells Controlling Streptococcus pneumoniae Infections Are Generated in the Spleen

  2003cited by this paper
• Humoral immunity and long-lived plasma cells.

  2002cited by this paper
• Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.

  2001cited by this paper
• Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus1

  2000cited by this paper
• Interleukin 6 Influences Germinal Center Development and Antibody Production via a Contribution of C3 Complement Component

  1998cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation

  1996cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995influential reference
• The role of interleukin-6 in mucosal IgA antibody responses in vivo.

  1994cited by this paper
• Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

  1993cited by this paper
• In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells.

  1991cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

  1988cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.

  1988cited by this paper
• [Erythematosus].

  1971cited by this paper

• Long-Term Effect and Safety of Tocilizumab on Severe Adult-Onset Still’s Disease Accompanied by Thrombotic Thrombocytopenic Purpura

  2025cites this paper
• Change of autoantibody levels in established rheumatoid arthritis patients treated by biological disease-modifying anti-rheumatic drugs -the AIRTIGHT study-

  2025cites this paper
• B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases

  2025cites this paper
• Tocilizumab is effective in preventing ovarian injury induced by ischemia- reperfusion in rats.

  2023cites this paper
• Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

  2023cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• Current status and prospects of IL-6–targeting therapy

  2022cites this paper
• Concomitant loss of regulatory T and B cells is a distinguishing immune feature of antibody-mediated rejection in kidney transplantation.

  2022cites this paper
• B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• A comparative study of adjuvants effects on neonatal plasma cell survival niche in bone marrow and persistence of humoral immune responses

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• Améliorer l’accès à la transplantation rénale des sujets hyperimmunisés : quelle place pour un blocage de la voie de l’IL-6 dans les protocoles de désimmunisation ?

  2022cites this paper
• [Improving access to kidney transplantation for highly sensitized patients: What place for IL-6 pathway blockade in desensitization protocols?]

  2022cites this paper
• COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS

  2022cites this paper
• Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection

  2021cites this paper
• The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response

  2021cites this paper
• Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates

  2021cites this paper
• Immune responses following tocilizumab therapy to desensitize HLA‐sensitized kidney transplant candidates

  2021cites this paper
• Can rheumatologists stop causing demyelinating disease?

  2021cites this paper
• Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells.

  2021cites this paper
• Immunological considerations—HLA matching and management of high immunological risk recipients

  2021cites this paper
• Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review

  2021cites this paper
• B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders

  2021cites this paper
• Regulatory B cells: TIM‐1, transplant tolerance, and rejection

  2021cites this paper
• Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies

  2020cites this paper
• Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients

  2020cites this paper
• Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

  2020cites this paper
• Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients

  2020cites this paper
• Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".

  2020cites this paper
• Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic

  2020cites this paper
• Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study

  2019cites this paper
• Acceleration of nano‐surface and molecular‐orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab

  2019cites this paper
• Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study

  2019cites this paper
• B cell subpopulations in the pathogenesis of rheumatoid arthritis

  2019cites this paper
• Evidence for the important role of inflammation in xenotransplantation

  2019cites this paper
• Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies

  2018cites this paper
• Selective CD28 Inhibition Modulates Alloimmunity and Cardiac Allograft Vasculopathy in Anti–CD154-Treated Monkeys

  2018cites this paper
• A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

  2018cites this paper
• Physiological effects of modulating the interleukin-6 axis

  2018cites this paper
• Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis

  2018cites this paper
• ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease

  2018cites this paper
• Immunogénicité du tocilizumab chez des patients atteints de polyarthrite rhumatoïde

  2018cites this paper
• Novel Drugs in Kidney Transplantation

  2017cites this paper
• B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

  2017cites this paper
• A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis

  2017cites this paper
• Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica

  2017cites this paper
• Immunogenicity of tocilizumab in patients with rheumatoid arthritis.

  2017cites this paper
• The role and therapeutic targeting of IL-6 in rheumatoid arthritis

  2017cites this paper
• Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future

  2016cites this paper
• B cell phenotype and function in granulomatosis with polyangiitis Land

  2016cites this paper
• Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis

  2016cites this paper
• Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis

  2016cites this paper
• B cell phenotype and function in granulomatosis with polyangiitis: Towards prediction of relapse

  2016cites this paper
• Distinct Differentiation Programs Triggered by IL-6 and LPS in Teleost IgM+ B Cells in The Absence of Germinal Centers

  2016cites this paper
• Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

  2016cites this paper
• Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases

  2015cites this paper
• Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors

  2015cites this paper
• Phenotypic and functional characterization of B-lineage cells associated with relapse and response to B-cell depletion therapy for rheumatoid arthritis

  2015cites this paper
• TNF INHIBITORS IN THERAPY OF RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISEASES

  2015cites this paper
• Novel therapies for memory cells in autoimmune diseases

  2015cites this paper
• Rational clinical trial design for antibody mediated renal allograft injury.

  2015cites this paper
• Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab.

  2015cites this paper
• Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?

  2015cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

  2015cites this paper
• [Effector B cells in autoimmune diseases].

  2015cites this paper
• Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response

  2015cites this paper
• A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

  2015cites this paper
• High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

  2015cites this paper
• CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis

  2015cites this paper
• Влияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данные

  2015cites this paper
• B cells: depletion or functional modulation in rheumatic diseases

  2014cites this paper
• Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis

  2014cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

  2014cites this paper
• Targeting of Interleukin-6 for the Treatment of Rheumatoid Arthritis: A Review and Update

  2014cites this paper
• Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance

  2014cites this paper
• Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report

  2014influential citation
• Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses

  2014cites this paper
• Роль лабораторных биомаркеров в мониторинге и прогнозировани и эффективности терапии ревматических заболеваний генно-инженерным и биологическими препаратами

  2014cites this paper
• Atacicept as an investigated therapy for rheumatoid arthritis

  2014cites this paper
• Modern anti-cytokine therapy of autoimmune diseases

  2014cites this paper
• Infektanfälligkeit unter antirheumatischer Therapie in Korrelation mit Serum-Immunglobulinspiegeln

  2013cites this paper
• Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis

  2013cites this paper
• Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab

  2013cites this paper
• The effect of targeted rheumatoid arthritis therapies on anti‐citrullinated protein autoantibody levels and B cell responses

  2013cites this paper
• Analysis of the Mechanism of Action of Biological Therapies in Monotherapy in Patients with Rheumatoid Arthritis: Beyond the ADACTA Study

  2013cites this paper
• Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.

  2013cites this paper
• Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

  2013cites this paper
• Immunotherapy of Tocilizumab for Rheumatoid Arthritis

  2013cites this paper
• Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab

  2013cites this paper
• [Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?].

  2013cites this paper
• Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

  2013cites this paper
• The past : advances permitting transplantation across immunological barriers Methodology to detect and monitor antibody

  2012cites this paper
• Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

  2012cites this paper
• The influence of biologic therapy on the capacity of regulatory T cells to restrain Th17 responses

  2012cites this paper
• Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.

  2012cites this paper
• To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra

  2012cites this paper